Characterization of the electrical and extracellular matrix remodeling in patients with HF: comparison between HEPF and HERF.

Gabriel da S. Ferreira*, Fernando B. Cardoso MD, Luis M. Silva BSc, Camilla Toledo BSc, Lígia M. Antunes-Correia PhD, Vinicius C. Ribeiro MD, Thiago Q. A. C. Silva MD PhD, Layde R. Paim BSc, Gustavo Martins MD, Wilson Nadruz MD PhD, Celso D. Ramos MD PhD, Andrei Sposito MD PhD, Jose R. Matos-Souza MD PhD, Tomas G. Neilan MD MPH, Michael Jerosch-Herold PhD, Otávio R. Coelho-Filho MD PhD MPH

Abstract

This study aimed to assess and compare myocardial electrical and extracellular matrix remodeling in patients with heart failure (HF) with preserved ejection fraction (HFpEF) and with heart failure with reduced ejection fraction (HFrEF) using a contemporary multimodality approach. We recruited 47 individuals presenting HF (22 females, 25 males), NYHA classes II-III, stratified according to LVEF in HFpEF (n=23) and HFrEF (n=24). They underwent cardiac MRI (CMR) including T1-mapping, echocardiography for global longitudinal strain (GLS), cardiopulmonary exercise test (CPET), cardiac sympathetic imaging with mIBG and biomarkers. Results show native-T1 and extracellular volume fraction (ECV) were not different between groups. The mIBG derived heart-to-mediastinum ratio (HMR) were reduced in both groups. Considering the entire cohort, as well as the HFrEF subgroup separately, ECV was inversely associated to HMR and to adjusted VO₂ max, and positively associated to NT-proBNP, US-Troponin and to GLS. Considering the HFpEF subgroup separately, only ECV and GLS association remained significant. The study highlights that similar extracellular matrix remodeling, assessed by ECV, between both subgroups confirms diffuse fibrosis as part of the HFpEF cardiac phenotype, which may partially explain its unfavorable prognosis and limited response to anti-remodeling therapies.

Key words: Heart failure, Preserved ejection fraction, Cardiac remodeling

Introduction

Individuals with heart failure (HF) with preserved ejection fraction (HFpEF) experience high morbidity and mortality, but contrary to HF with reduced EF (HFrEF), anti-remodeling therapies have failed to reduce mortality. Current methods to detect LV reverse remodeling reveal primarily advanced disease and fail to detect tissue phenotypes of early-HF-stages. We aimed to investigate and compare myocardial tissue remodeling in HFpEF and HFrEF using a contemporary multimodality approach to assess myocardial electrical and extracellular matrix remodeling.

Results and Discussion

Forty-seven individuals (age: 54.1±11 years, BMI: 30.5±6, 22 females, mean-LVEF: 42.2±15%, 24 HFrEF and 23 HFpEF) were prospectively recruited. They were symptomatic HF patients (NYHA II-III) stratified according to LVEF in HFrEF (<50%) and HFpEF (≥50%) and underwent cardiac MRI (CMRI) including T1-mapping, echocardiography for global longitudinal strain (GLS), cardiopulmonary exercise test (CPET), cardiac sympathetic imaging with mIBG and biomarkers. All individuals were recruited when stabilized using optimized HF therapy. As expected LVEF was different between groups (32±8.5% vs. 58.2±7%, p<0.001) and the adjusted-VO2max was more reduced in HFrEF (18.3±4.7 vs. 22.8±5.2 ml/min/kg, p=0.01). While GLS was reduced in HFrEF compared to HFpEF (HFrEF:-8.2±3.7% vs. HFpEF:-15.2±3.7%, p<0.001), both the native-T1 (HFrEF:1101.6±213 vs. HFpEF:1146±58, p=0.4) and extracellular volume fraction (ECV), though abnormally high, were not different among HF groups (HFrEF:0.36±0.07 vs. HFpEF:0.33±0.03, p=0.06). The mIBG derived heart-to-mediastinum ratio (HMR) were also reduced in both groups but more evident in the HFrEF (1.44±0.17 vs. 1.62±0.21, p=0.007). Considering the entire cohort, ECV was inversely associated to HMR (r=-0.45, p=0.023) and to adjusted-VO2max (r=-0.41, p=0.02); and positively associated to NT-proBNP (r=0.52, p=0.001), US-Troponin (r=0.6, p=0.009) and to GLS (r=0.59, p<0.001). While all these associations were maintained in HFrEF, only the association of ECV and GLS remained significant (r=0.7, p<0.05) in the HFpEF subgroup.

Conclusions

This study highlights the considerable myocardial tissue remodeling present in patients with HFpEF. Extracellular matrix remodeling, assessed by ECV, was similar in HFpEF and HFrEF, confirming that diffuse fibrosis is part of the HFpEF cardiac phenotype, which may partially explain its unfavorable prognosis and limited response to anti-remodeling therapies seen in contemporary clinical trials.

Acknowledgement

This research was supported by CNPQ, Fapesp and FAEPEX.


DOI: 10.20396/revpibic.